Minnesota HF 4852: Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Status: Introduction and first reading, referred to Health Finance and Policy (as of 2026-04-07)

State: Minnesota · Session: 2025-2026 · Bill: HF 4852

Subjects: Health and Health Department, Human Services and Human Services Department

Sponsors: Reyer, Bierman

View Minnesota HF 4852 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.